Distinct metabolomic profiles in lean and non-lean polyendocrine metabolic ovarian syndrome
Abstract
Purpose: Polycystic ovary syndrome (PCOS)/polyendocrine metabolic ovarian syndrome (PMOS) is the most prevalent endocrine disorder in reproductive-age women and is characterized by long-term metabolic consequences. The purpose of this study is to delineate the metabolomic profile in lean and non-lean PMOS patients.
Methods: Retrospective cross-sectional study includes 4768 premenopausal patients with available body mass index (BMI) and metabolomics information at the Mass General Brigham (MGB) Biobank. The Biobank includes samples collected from 05/2010 to 08/2023 with unique metabolomic biomarkers that encompass key metabolic pathways, including lipids, amino acids, and glycolysis-related metabolites. The main outcome measures were metabolomic profile differences between PMOS (n = 403) and non-PMOS patients (n = 4365). Sub-analyses were performed within normal BMI (2), overweight BMI (25-29.9 kg/m2), and obesity BMI (≥ 30 kg/m2) subgroups.
Results: PMOS patients were younger (p < 0.001) and had higher BMI (p < 0.001). When considering the total population and adjusting for age, BMI, exercise, metformin, oral contraceptive pills (OCPs), and glucagon like peptide-1 (GLP-1) agonists, PMOS affected the expression of only 1/71 (1.4%) parameter compared to the non-PMOS group. In the normal BMI sub-group, there were no differences in any of the metabolomic parameters when controlling for age, exercise, metformin, OCPs, and GLP-1 agonists except for creatinine levels that were…
How strong is the evidence?
Evidence Hub reads this as a cross-sectional, done in people. Its evidence level is 4 of 5 (Low · observational). Observational designs can show an association but not prove cause. Reported size: 4,768 participants or records.
Read the paper
Related studies
- Increased expression of circulating miRNA-93 in women with polycystic ovary syndrome may represent a novel, non-invasive biomarker for diagnosis
- Identification of key genes associated with polycystic ovary syndrome (PCOS) and ovarian cancer using an integrated bioinformatics analysis
- Identification of key pathways and genes in polycystic ovary syndrome via integrated bioinformatics analysis and prediction of small therapeutic molecules
- Regulation of Androgen Receptor Expression Alters AMPK Phosphorylation in the Endometrium: In Vivo and In Vitro Studies in Women with Polycystic Ovary Syndrome
- Effect of oral administration of low-dose follicle stimulating hormone on hyperandrogenized mice as a model of polycystic ovary syndrome
- Systems pharmacology to investigate the interaction of berberine and other drugs in treating polycystic ovary syndrome
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.